Department of Biochemical Engineering and Biotechnology, Indian Institute of Technology Delhi, New Delhi, India.
Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Int J Cancer. 2019 Sep 1;145(5):1254-1269. doi: 10.1002/ijc.32360. Epub 2019 May 10.
Recent advancement in understanding cancer etiology has highlighted epigenetic deregulation as an important phenomenon leading to poor prognosis in glioblastoma (GBM). Polycomb repressive complex 2 (PRC2) is one such important epigenetic modifier reportedly altered in GBM. However, its defined mechanism in tumorigenesis still remains elusive. In present study, we analyzed our in-house ChIPseq data for H3k27me3 modified miRNAs and identified miR-490-3p to be the most common target in GBM with significantly downregulated expression in glioma patients in both TCGA and GBM patient cohort. Our functional analysis delineates for the first time, a central role of PRC2 catalytic unit EZH2 in directly regulating expression of this miRNA and its host gene CHRM2 in GBM. In accordance, cell line treatment with EZH2 siRNA and 5-azacytidine also confirmed its coregulation by CpG and histone methylation based epigenetic mechanisms. Furthermore, induced overexpression of miR-490-3p in GBM cell lines significantly inhibited key hallmarks including cellular proliferation, colony formation and spheroid formation, as well as epithelial-to-mesenchymal transition (EMT), with downregulation of multiple EMT transcription factors and promigratory genes (MMP9, CCL5, PIK3R1, ICAM1, ADAM17 and NOTCH1). We also for the first time report TGFBR1 and TGIF2 as two direct downstream effector targets of miR-490-3p that are also deregulated in GBM. TGIF2, a novel target, was shown to promote migration and EMT that could partially be rescued by miR-490-3p overexpression. Overall, this stands as a first study that provides a direct link between epigenetic modulator EZH2 and oncogenic TGF-β signaling involving novel miR-490-3p/TGIF2/TGFBR1 axis, that being targetable might be promising in developing new therapeutic intervention strategies for GBM.
近年来,对癌症病因学的深入了解强调了表观遗传失调是导致胶质母细胞瘤(GBM)预后不良的重要现象。多梳抑制复合物 2(PRC2)是一种重要的表观遗传修饰物,据报道在 GBM 中发生改变。然而,其在肿瘤发生中的明确机制仍然难以捉摸。在本研究中,我们分析了我们内部的 ChIPseq 数据,以确定 H3k27me3 修饰的 miRNA,并鉴定出 miR-490-3p 是 GBM 中最常见的靶标,在 TCGA 和 GBM 患者队列中,胶质瘤患者的表达明显下调。我们的功能分析首次描述了 PRC2 催化亚单位 EZH2 在直接调节该 miRNA 及其宿主基因 CHRM2 在 GBM 中的表达方面的核心作用。相应地,细胞系用 EZH2 siRNA 和 5-氮杂胞苷处理也证实了其基于 CpG 和组蛋白甲基化的表观遗传机制的共同调节。此外,在 GBM 细胞系中诱导过表达 miR-490-3p 可显著抑制多种关键特征,包括细胞增殖、集落形成和球体形成,以及上皮间质转化(EMT),同时下调多个 EMT 转录因子和促迁移基因(MMP9、CCL5、PIK3R1、ICAM1、ADAM17 和 NOTCH1)。我们还首次报道 TGFBR1 和 TGIF2 作为 miR-490-3p 的两个直接下游效应靶标,它们在 GBM 中也失调。作为一个新的靶标,TGIF2 被证明可促进迁移和 EMT,而过表达 miR-490-3p 可部分挽救这种情况。总的来说,这是第一项研究,提供了表观遗传调节剂 EZH2 与涉及新的 miR-490-3p/TGIF2/TGFBR1 轴的致癌 TGF-β 信号之间的直接联系,该轴可能是有希望的,可为开发新的 GBM 治疗干预策略提供依据。